Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]

Core Viewpoint - INVO Fertility, Inc. is positioned for growth with a strengthened fundamental position, focusing on operational progress, disciplined capital management, and a clear growth strategy [3][4][21]. Operational Progress - The company has three operational fertility clinics generating positive cash flow, marking a critical milestone in achieving profitability at the clinic level [5]. - INVO Fertility is nearing the acquisition of a fourth clinic in Indianapolis, which will diversify revenue and enhance earnings power [6]. Financial Performance - The combined pro forma annualized revenue run rate from all clinics is approximately $9 million, providing a strong baseline for growth [7]. - The company has simplified and strengthened its capital structure, with recent financing issued at a fixed price of $1.59, enhancing clarity and alignment for shareholders [16][17]. Growth Strategy - Organic growth is a key component of the strategy, focusing on increasing patient volumes and optimizing treatment pathways [8][9]. - Acquisitions are a cornerstone of growth, with a robust pipeline of potential targets under evaluation, emphasizing clinics with strong reputations and operational improvement opportunities [10][11][12]. Market Environment - Recent executive actions support federal access to IVF and fertility treatments, potentially increasing patient demand and utilization of fertility services [13]. - The company anticipates strong growth in 2026, driven by acquisitions and organic expansion, addressing the rising global infertility rates and limited access to affordable services [14][15]. Future Outlook - INVO Fertility is positioned for a higher-growth phase with a stabilized operational base and a strong balance sheet, aiming to build a scalable platform for sustained growth [19][21].

Core Viewpoint - INVO Fertility Inc. has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants, resulting in expected gross proceeds of approximately $7.5 million [1][3]. Group 1: Warrant Inducement Agreement - The investor has agreed to a reduced exercise price of the December 2025 Warrants to $1.59, allowing the purchase of 4,733,728 shares of common stock [1]. - In exchange for the immediate exercise of existing warrants, the company will issue unregistered warrants to purchase an additional 9,467,456 shares at the same exercise price of $1.59, subject to shareholder approval [3]. - The closing of the warrant exercise transactions is anticipated to occur on or about January 30, 2026, pending customary closing conditions [4]. Group 2: Financial Advisory and Compliance - Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction [2]. - The New Warrants are being offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933, and have not been registered under the Act [5]. Group 3: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) care, operating fertility clinics and offering the INVOcell medical device [7]. - The company has two operational INVO Centers in the U.S. and one IVF clinic, and continues to sell and distribute INVOcell to third-party clinics [7]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more intimate and affordable experience compared to traditional IVF [7].

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].

Core Viewpoint - INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, P.C., marking a significant step in its strategy to expand its fertility care centers across the United States [1][2]. Group 1: Acquisition Details - The purchase agreement follows the announcement made on November 27, 2025, regarding the intent to acquire Family Beginnings [2]. - Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the 12-month period ending September 30, 2025 [2]. - The total purchase price for the acquisition is $750,000, with $350,000 to be paid in cash at closing and $400,000 in preferred stock [4]. Group 2: Strategic Importance - The acquisition aligns with INVO's mission to enhance access to advanced fertility care and expand its operational footprint [3]. - Family Beginnings is recognized for its strong clinical reputation and offers a comprehensive range of reproductive services, including IVF and fertility preservation [3]. Group 3: Leadership and Integration - Dr. James Donahue will continue to lead Family Beginnings under a three-year agreement following the acquisition [4]. - The integration of Family Beginnings into INVO's operations is anticipated to build upon the existing foundation and further grow the practice in the local market [3].

Core Viewpoint - INVO Fertility, Inc. has announced a private placement offering to raise approximately $4.0 million through the sale of common stock and warrants, aimed at expanding its operations in the fertility market [1][2]. Group 1: Offering Details - The company will sell 2,366,864 shares of common stock and warrants to purchase up to 4,733,728 additional shares, with a combined effective offering price of $1.69 per share [1]. - The warrants will have an exercise price of $1.69 per share, exercisable upon shareholder approval, and will expire five years from the date of such approval [1]. - The offering is expected to close on or about December 3, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - Gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses related to the placement [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. Group 3: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell technology [5]. - The company operates two INVO Centers and one IVF clinic in the United States, offering the intravaginal culture (IVC) procedure, which is designed to provide a more natural and cost-effective alternative to traditional IVF [5]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, potentially delivering comparable results to traditional methods at a lower cost [5].

Core Insights - INVO Fertility, Inc. is set to acquire Family Beginnings, P.C., enhancing its national expansion strategy and clinical capabilities in the Midwest [1][4] - This acquisition follows INVO's previous purchase of Wisconsin Fertility Institute in 2023, indicating a strategic initiative to build a nationwide network of fertility centers [1][4] Company Overview - INVO Fertility focuses on establishing, acquiring, and operating fertility clinics and related technologies, with a commitment to expanding access to assisted reproductive technology (ART) [8] - The company operates two INVO Centers and one IVF clinic in the U.S., and is engaged in the sale and distribution of its proprietary INVOcell medical device [8] Acquisition Details - Family Beginnings is recognized for its high standards of care and has served thousands of patients in Indiana and surrounding states, offering a full suite of reproductive services [2][3] - The acquisition aims to introduce expanded treatment options, invest in clinic infrastructure, and integrate digital patient engagement tools [6] - The transaction is subject to customary due diligence and negotiation of definitive purchase agreements [4][7] Strategic Goals - The acquisition aligns with INVO's mission to make fertility care more accessible and patient-centered, leveraging strategic acquisitions to accelerate growth [4] - INVO plans to enhance the Family Beginnings clinic by broadening offerings and ensuring high-quality care for more patients [3][6]

Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-8 reverse stock split effective November 28, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - INVO Fertility is a healthcare services company focused on the fertility market, particularly in expanding assisted reproductive technology (ART) care [3]. - The company's strategy includes building, acquiring, and operating fertility clinics, specifically "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device [3]. - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States and distributes the INVOcell technology to third-party fertility clinics [3]. - The IVC procedure is designed to provide a more natural, intimate, and cost-effective alternative to traditional IVF, with comparable results at a lower cost [3].

Core Insights - INVO Fertility reported a strong financial performance in Q3 2025, with total revenue increasing by 23% year-over-year to $1,757,094, driven by higher patient volumes and enhanced marketing efforts [5][4] - The company achieved 18% organic growth across its clinics, attributed to increased patient flow and expanded telehealth capabilities [5][4] - The recent policy updates allowing employers to offer standalone infertility benefits are expected to further enhance access to IVF treatments, contributing to industry growth [5][4] Financial Highlights - Total revenue for Q3 2025 was $1,757,094, up from $1,433,151 in Q3 2024, marking a 23% increase [5] - Consolidated clinic revenue increased by 21% to $1,722,223 compared to $1,418,011 in the previous year [5] - The net loss for the quarter was $(2.6) million, compared to $(1.6) million in Q3 2024 [5] Operational and Strategic Highlights - The company is focused on strengthening organic performance and pursuing acquisition opportunities, with a pipeline of target clinics for potential acquisition [4] - INVOcell device revenue grew by 130% year-over-year, reflecting successful expansion initiatives and improved pricing strategies [5][4] - Operational efficiencies are being pursued through partnerships, such as with Heidi Health for AI-powered solutions [5][6] Management Commentary - The CEO emphasized the importance of organic growth and acquisition strategies in driving the company's mission to enhance patient access to fertility services [4] - The company is committed to operational efficiency to achieve profitability while expanding its services [6]